Prestige Consumer Healthcare Past Earnings Performance
Past criteria checks 0/6
Prestige Consumer Healthcare's earnings have been declining at an average annual rate of -1.6%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 4.2% per year.
Key information
-1.6%
Earnings growth rate
-1.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 4.2% |
| Return on equity | -5.0% |
| Net Margin | -7.1% |
| Next Earnings Update | 14 May 2024 |
Recent past performance updates
Recent updates
Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Mar 26
An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 50% Undervalued
Mar 05Prestige Consumer Healthcare Inc. (NYSE:PBH) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Feb 11Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Shares May Have Run Too Fast Too Soon
Feb 05Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Dec 14Prestige Consumer Healthcare (NYSE:PBH) Seems To Use Debt Quite Sensibly
Sep 10Prestige Consumer Healthcare: Unproductive Buyback And Excessive Valuation
Aug 15Is Prestige Consumer Healthcare (NYSE:PBH) Using Too Much Debt?
Jun 12An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 43% Undervalued
May 20Here's Why Prestige Consumer Healthcare (NYSE:PBH) Has Caught The Eye Of Investors
Mar 17Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Mar 02Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Intrinsic Value Is Potentially 75% Above Its Share Price
Feb 08Prestige Consumer Healthcare reports Q3 earnings beat; updates FY23 guidance
Feb 02Prestige Consumer Healthcare: Taking My Winnings Off The Table
Jan 19Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Nov 23Prestige Consumer Healthcare GAAP EPS of $1.02 beats by $0.02, revenue of $289.3M beats by $6.07M
Nov 03Holding Prestige Consumer Healthcare
Aug 31If EPS Growth Is Important To You, Prestige Consumer Healthcare (NYSE:PBH) Presents An Opportunity
Aug 26We Think Prestige Consumer Healthcare (NYSE:PBH) Can Stay On Top Of Its Debt
Aug 05Prestige Consumer Healthcare GAAP EPS of $1.09 beats by $0.05, revenue of $277.1M beats by $8.18M
Aug 04Should You Be Adding Prestige Consumer Healthcare (NYSE:PBH) To Your Watchlist Today?
May 27Is Prestige Consumer Healthcare (NYSE:PBH) A Risky Investment?
May 05Does Prestige Consumer Healthcare (NYSE:PBH) Deserve A Spot On Your Watchlist?
Feb 22Is Prestige Consumer Healthcare (NYSE:PBH) A Risky Investment?
Feb 03These 4 Measures Indicate That Prestige Consumer Healthcare (NYSE:PBH) Is Using Debt Extensively
Nov 04Here's Why Prestige Consumer Healthcare (NYSE:PBH) Has A Meaningful Debt Burden
Aug 06Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jun 14Prestige Consumer Healthcare Inc. 2021 Q4 - Results - Earnings Call Presentation
May 08These 4 Measures Indicate That Prestige Consumer Healthcare (NYSE:PBH) Is Using Debt Extensively
Apr 19How Much Did Prestige Consumer Healthcare's (NYSE:PBH) CEO Pocket Last Year?
Feb 22Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow Prestige Consumer Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,134 | -81 | 254 | 0 |
| 30 Sep 23 | 1,127 | -82 | 246 | 0 |
| 30 Jun 23 | 1,130 | -84 | 250 | 0 |
| 31 Mar 23 | 1,128 | -82 | 252 | 0 |
| 31 Dec 22 | 1,109 | 210 | 252 | 0 |
| 30 Sep 22 | 1,108 | 209 | 262 | 0 |
| 30 Jun 22 | 1,095 | 203 | 264 | 0 |
| 31 Mar 22 | 1,087 | 205 | 260 | 0 |
| 31 Dec 21 | 1,058 | 189 | 261 | 0 |
| 30 Sep 21 | 1,022 | 179 | 255 | 0 |
| 30 Jun 21 | 983 | 179 | 240 | 0 |
| 31 Mar 21 | 943 | 165 | 224 | 0 |
| 31 Dec 20 | 957 | 166 | 230 | 0 |
| 30 Sep 20 | 960 | 163 | 225 | 0 |
| 30 Jun 20 | 960 | 152 | 227 | 0 |
| 31 Mar 20 | 963 | 142 | 236 | 0 |
| 31 Dec 19 | 953 | -34 | 224 | 0 |
| 30 Sep 19 | 953 | -34 | 224 | 0 |
| 30 Jun 19 | 954 | -36 | 224 | 0 |
| 31 Mar 19 | 976 | -36 | 233 | 0 |
| 31 Dec 18 | 991 | 64 | 231 | 0 |
| 30 Sep 18 | 1,020 | 340 | 233 | 0 |
| 30 Jun 18 | 1,039 | 340 | 233 | 0 |
| 31 Mar 18 | 1,041 | 340 | 229 | 0 |
| 31 Dec 17 | 1,026 | 390 | 227 | 0 |
| 30 Sep 17 | 972 | 107 | 223 | 0 |
| 30 Jun 17 | 929 | 109 | 210 | 0 |
| 31 Mar 17 | 882 | 69 | 199 | 0 |
| 31 Dec 16 | 849 | 72 | 190 | 0 |
| 30 Sep 16 | 833 | 69 | 186 | 0 |
| 30 Jun 16 | 824 | 68 | 183 | 0 |
| 31 Mar 16 | 806 | 100 | 179 | 0 |
| 31 Dec 15 | 788 | 110 | 166 | 0 |
| 30 Sep 15 | 786 | 103 | 167 | 0 |
| 30 Jun 15 | 761 | 88 | 180 | 0 |
| 31 Mar 15 | 715 | 78 | 167 | 0 |
| 31 Dec 14 | 668 | 70 | 167 | 0 |
| 30 Sep 14 | 615 | 52 | 154 | 0 |
| 30 Jun 14 | 601 | 69 | 134 | 0 |
| 31 Mar 14 | 597 | 73 | 132 | 0 |
| 31 Dec 13 | 609 | 76 | 138 | 0 |
| 30 Sep 13 | 624 | 85 | 135 | 0 |
| 30 Jun 13 | 619 | 72 | 135 | 0 |
Quality Earnings: PBH is currently unprofitable.
Growing Profit Margin: PBH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PBH is unprofitable, and losses have increased over the past 5 years at a rate of 1.6% per year.
Accelerating Growth: Unable to compare PBH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PBH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.8%).
Return on Equity
High ROE: PBH has a negative Return on Equity (-5.04%), as it is currently unprofitable.